<DOC>
	<DOCNO>NCT00025038</DOCNO>
	<brief_summary>Giving chemotherapy drug , R115777 , isotretinoin , cytarabine , fludarabine , donor bone marrow transplant umbilical cord transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . This phase II trial study well give combination chemotherapy together donor bone marrow umbilical cord blood transplant work treat child newly diagnose juvenile myelomonocytic leukemia</brief_summary>
	<brief_title>Combination Chemotherapy Followed By Donor Bone Marrow Umbilical Cord Blood Transplant Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate child newly diagnose juvenile myelomonocytic leukemia treat R115777 , isotretinoin , cytarabine , fludarabine follow allogeneic bone marrow umbilical cord blood transplantation . II . Determine safety toxicity regimen patient . III . Determine tolerability regimen patient . IV . Determine rate 2-year event-free survival patient treat regimen . V. Determine whether prognostic subset patient identify base expression clinical , genetic ( NFI , monosomy 7 , RAS gene ) , hematopoietic characteristic . OUTLINE : This multicenter study . Patients may choose receive upfront window induction therapy oral R115777 twice daily day 1-21 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . Patients progressive disease stable disease unacceptable hematopoietic recovery 1 course proceed induction chemotherapy . ( R11577 portion study close accrual 08/2005 ) All patient receive induction chemotherapy comprise oral isotretinoin daily begin day 1 fludarabine IV 30 minute cytarabine IV 4 hour day 1-5 . Treatment fludarabine cytarabine repeat every 28 day 2 course . Treatment isotretinoin continue allogeneic bone marrow umbilical cord blood transplantation . Patients progressive disease 1 course proceed transplantation . After completion isotretinoin , patient receive preparative regimen comprise total body irradiation twice daily day -7 -4 , cyclophosphamide IV 2 hour day -3 -2 , anti-thymocyte globulin IV 4-6 hour every 12 hour day -3 -1 . Patients undergo allogeneic bone marrow umbilical cord blood transplantation day 0 . Patients receive oral isotretinoin daily begin approximately day 60 continue 1 year . Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A maximum 100 patient ( 18-46 receiving R115777 induction chemotherapy [ R11577 portion study close accrual 08/2005 ] 27-54 receive induction chemotherapy ) accrue study within 3.2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>Newly diagnose , previously untreated juvenile myelomonocytic leukemia Presenting follow : Absence ( 9 ; 22 ) bcr/abl PCR Absolute monocyte count great 1,000/mm^3 Less 20 % bone marrow blast Presenting least 2 follow : Elevated F hemoglobin Myeloid precursor peripheral blood WBC great 10,000/mm^3 Sargramostim ( GMCSF ) hypersensitivity See Disease Characteristics Bilirubin great 2.0 mg/dL ALT great 3 time normal Creatinine great 2 time normal No concurrent sargramostim ( GMCSF ) No concurrent proton pump inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>